ArticleFrontiers in oncology2022

Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study.

Caiyun Nie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.